Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Fineline Cube May 18, 2026
Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Fineline Cube May 18, 2026
Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Fineline Cube May 18, 2026
Company Deals

Sinopharm Partners with Fudan University to Establish National Innovation Platform

Fineline Cube May 8, 2023

China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strategic partnership with Fudan...

Company Drug

Reistone Biopharma’s Edralbrutinib Earns Orphan Drug Designation for NMOSD from US FDA

Fineline Cube May 8, 2023

Reistone Biopharma Co., Ltd, a company incubated by Hengrui Medicine with an investment of USD...

Company Deals

Lingyi Biotechnology Secures RMB 100 Million in Series A Funding for Gene Therapy Pipeline

Fineline Cube May 6, 2023

China-based gene therapy developer Lingyi Biotechnology Co., Ltd has reportedly raised close to RMB 100...

Company Drug

Henlius Biotech’s HLX26 and HaiSiZhuang Combo for NSCLC Gets NMPA Phase II Approval

Fineline Cube May 6, 2023

Shanghai Henlius Biotech (HKG: 2696) has announced that it has received approval from the National...

Company Deals

Shanghai Junshi Biosciences Inks Exclusive License Deal with Dr. Reddy’s Laboratories for Tuoyi

Fineline Cube May 6, 2023

Shanghai Junshi Biosciences Co., Ltd (SHA: 688180), a China-based biotechnology firm, has announced an exclusive...

Company Deals

Sinopharm Partners with Shenzhen to Boost High-End Medical Device and Pharmaceutical Innovation

Fineline Cube May 6, 2023

China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strategic partnership with Shenzhen...

Company Deals

XtalPi Inc. and China Pharmaceutical University Launch Joint AI Research Center in China

Fineline Cube May 6, 2023

Sino-US artificial intelligence (AI) firm XtalPi Inc. has joined forces with China Pharmaceutical University (CPU)...

Company Medical Device

Omega Medical Imaging’s Soteria.AI Receives FDA Approval for Interventional Cardiology

Fineline Cube May 6, 2023

US-based medical technology firm Omega Medical Imaging has received marketing approval from the US Food...

Policy / Regulatory

NMPA Extends Public Feedback Period for ‘Drug Standardization Management Measures’ in China

Fineline Cube May 6, 2023

The National Medical Products Administration (NMPA) in China has announced an extension to the public...

Company Deals

Hasten Biopharm Acquires Commercial Rights to Rocephin in China from Roche

Fineline Cube May 6, 2023

China-based Hasten Biopharmaceutical Co., Ltd has announced the acquisition of the commercial rights in China...

Company

Mindray Reports Strong YOY Growth in 2022 and Q1 2023 Financial Results

Fineline Cube May 6, 2023

China-based medical device firm Mindray (SHE: 300760) has released its financial reports for the year...

Policy / Regulatory

Anhui and Qinghai Provinces Update BMI Chronic Disease Drug Lists for Outpatient Reimbursement

Fineline Cube May 6, 2023

The healthcare security bureaus of Anhui and Qinghai provinces in China have separately released notifications...

Company Drug

Huadong Medicine’s Mefatinib Poised for Breakthrough Therapy Designation by CDE

Fineline Cube May 6, 2023

The Center for Drug Evaluation (CDE) website indicates that China-based Huadong Medicine Co., Ltd (SHE:...

Company Deals

VivaVision Biotech Secures Over RMB 100 Million in Series D2 Financing for Ophthalmology Pipeline Expansion

Fineline Cube May 5, 2023

China’s VivaVision Biotech Inc. has announced the successful completion of its Series D2 financing round,...

Company Drug

Yantai Dongcheng Pharma’s 177Lu-LNC1003 Cleared for US FDA Phase I Study

Fineline Cube May 5, 2023

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced that it has received...

Company Drug

ABM Therapeutics’ ABM-168 Begins Phase I Dosing in the US for Advanced Solid Tumors

Fineline Cube May 5, 2023

Shanghai-based ABM Therapeutics, Inc. has announced the commencement of the first patient enrollment and dosing...

Company Deals

Kangrui Health Partners with West China Second University Hospital for Pediatric Care Innovation

Fineline Cube May 5, 2023

Kangrui Health, a leading data and intelligence application company based in Beijing, has entered into...

Policy / Regulatory R&D

China’s CDE Releases 69th Batch of Generic Chemical Reference Preparations for Public Review

Fineline Cube May 5, 2023

The Center for Drug Evaluation (CDE) in China has released the 69th batch of chemical...

Company Drug

Innovent Biologics’ GFH925 Earns Breakthrough Therapy Designation for KRASG12C CRC Treatment

Fineline Cube May 5, 2023

The Center for Drug Evaluation (CDE) website indicates that China-based Innovent Biologics’ (HKG: 1801) Category...

Company Drug

CARsgen Therapeutics’ AB011 and Tecentriq Combo Gets NMPA Approval for Gastric Cancer Treatment

Fineline Cube May 5, 2023

China-based chimeric antigen receptor (CAR)-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced...

Posts pagination

1 … 530 531 532 … 667

Recent updates

  • BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color
  • Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy
  • AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting
  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.